Please use this identifier to cite or link to this item:
|Title:||Inhibition of Nutlin-resistant HDM2 mutants by stapled peptides||Authors:||Wei, S.J.
|Issue Date:||20-Nov-2013||Citation:||Wei, S.J., Joseph, T., Chee, S., Li, L., Yurlova, L., Zolghadr, K., Brown, C., Lane, D., Verma, C., Ghadessy, F. (2013-11-20). Inhibition of Nutlin-resistant HDM2 mutants by stapled peptides. PLoS ONE 8 (11) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0081068||Abstract:||Pharmacological modulation of p53 activity is an attractive therapeutic strategy in cancers with wild-type p53. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2, a key negative regulator of p53 and blocks its activity. We have described resistance mutations in HDM2 that selectively reduce affinity for Nutlin but not p53. In the present communication, we show that stapled peptides targeting the same region of HDM2 as Nutlin are refractory to these mutations, and display reduced discrimination between the wild-type and mutant HDM2s with regards to functional abrogation of interaction with p53. The larger interaction footprint afforded by stapled peptides suggests that this class of ligands may prove comparatively more resilient to acquired resistance in a clinical setting. © 2013 Jia Wei et al.||Source Title:||PLoS ONE||URI:||http://scholarbank.nus.edu.sg/handle/10635/100932||ISSN:||19326203||DOI:||10.1371/journal.pone.0081068|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|10_1371_journal_pone_0081068.pdf||2.76 MB||Adobe PDF|
checked on Apr 6, 2020
WEB OF SCIENCETM
checked on Mar 26, 2020
checked on Mar 28, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.